Ironwood beats on 2026 outlook thanks to higher sales from AbbVie-partnered Linzess
Shares of Ironwood Pharmaceuticals (IRWD) added ~15% in the premarket on Friday after the company set its 2026 revenue...
Tag: ABBV
LENZ plunges after adverse event report on eye therapy
Shares of LENZ Therapeutics (LENZ) fell ~26% on Friday, a move TD Cowen attributed to investor worries over an adverse event...
Short bets on S&P 500 Healthcare sector rises to 2.12% in November; MRNA stays most shorted stock
The S&P 500 Healthcare sector (XLV) experienced a rise in average short interest during November, moving from 1.97% to...
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma
The U.S. Food and Drug Administration (FDA) on Tuesday announced the approval of Epkinly, a bispecific antibody developed...
Big pharma hits a record high as FDA picks new drug regulator
Shares of global drug companies reached a record high after the U.S. Food and Drug Administration (FDA) announced the...
Ironwood surges after Q3 beat; raised outlook for AbbVie-partnered Linzess
Shares of Ironwood Pharmaceuticals (IRWD) climbed ~34% on Monday after the company well exceeded Street forecasts with its...
FDA to remove “black box” warnings on hormone therapies for menopause
Marking a pivotal moment in women’s health, the U.S. Food and Drug Administration (FDA) on Monday initiated actions to...
Ironwood wins FDA label expansion for bowel disease drug developed with AbbVie
The U.S. Food and Drug Administration on Wednesday approved Linzess (linaclotide), developed by Ironwood Pharmaceuticals...
AbbVie raises 2025 EPS guidance and signals strong pipeline milestones into 2026
Earnings Call Insights: AbbVie Inc. (ABBV) Q3 2025 CEO Robert Michael stated that "AbbVie's business continues to perform...
AbbVie boosts 2025 EPS guidance but still falls short of consensus
While AbbVie (ABBV) raised its 2025 non-GAAP EPS guidance on Friday, it still falls short of the consensus figure. Shares...